Antidiabetic medications

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/155 (2006.01) A61K 9/00 (2006.01) A61K 9/20 (2006.01) A61K 9/28 (2006.01) A61K 9/48 (2006.01) A61K 31/522 (2006.01) A61K 45/06 (2006.01) A61P 3/08 (2006.01) A61P 3/10 (2006.01)

Patent

CA 2752437

The invention relates to antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia, inter alia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. The medication is a mono treatment with a DPP-4 inhibitor < preferably linagliptin > or a combination treatment with a DPP-4 inhibitor ans a second and/or third antidiabetic.

La présente invention concerne des médicaments antidiabétiques qui sont adaptés au traitement ou à la prévention d'une ou de plusieurs pathologies sélectionnées notamment parmi le diabète sucré de type 1, le diabète sucré de type 2, une mauvaise tolérance au glucose et l'hyperglycémie. En outre, la présente invention concerne des méthodes de prévention ou de traitement de troubles du métabolisme et de pathologies afférentes.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Antidiabetic medications does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antidiabetic medications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antidiabetic medications will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1789735

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.